Evidence map›Paper›PMID 42321189›Full record

ArticleNature communications2026

Scaling covalent ligand discovery through dynamic combinatorial library-versus-proteome screening.

Yuchen Huang, Lexuan Hou, Ruiping He, Lin Zhu, Caifeng Xu, Shixiang Duan, Jing Hu, Xi Yang, Yu-Hsuan Tsai, Chu Wang and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuchen Huang *Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Lexuan Hou *Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Ruiping He *Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, China.
Lin Zhu *Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Caifeng XuInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Shixiang DuanInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, China.
Jing HuInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Xi YangInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Yu-Hsuan TsaiInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, China.ORCID 0000-0003-0589-5088
Chu WangSynthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.ORCID 0000-0002-6925-1268
Chunmao HeSchool of Chemistry and Chemical Engineering, South China, University of Technology, Guangzhou, China. hecm@scut.edu.cn.ORCID 0000-0003-4596-0032
Xiaoyu LiDepartment of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong, SAR, China. xiaoyuli@hku.hk.ORCID 0000-0002-8907-6727
Li ChenShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, China. chenli_imib@fudan.edu.cn.ORCID 0000-0001-8685-3466
Gang LiInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China. ligang@szbl.ac.cn.ORCID 0000-0003-4434-4756

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22522703National Natural Science Foundation of China (National Science Foundation of China) 32422048
6 · The paper itself

Abstract

Mass spectrometry-based chemical proteomics enables unbiased assessment of ligand potency and selectivity across the proteome. However, current approaches remain limited by the low throughput of single-compound screening and reliance on pre-synthesized libraries. Here we devise a mechanism-driven "library-versus-proteome" platform that couples dynamic combinatorial libraries with activity-based protein profiling, enabling real-time selection and optimization of ligands in complex biological systems. This approach increases screening throughput by 10- to 20-fold, streamlines library generation, and adopts a "screen first, synthesize later" paradigm. Applying this platform, we discover covalent inhibitors of serine hydrolases including PPME1, ABHD11 and PNPLA6, and reveal uncharacterized roles of PNPLA6 in lipid metabolism and cancer cell proliferation. We further extend the strategy to cysteine-targeting ligands by designing tailored warheads, enabling proteome-wide EC50 profiling of over 2600 ligandable cysteines and yielding inhibitors for NIT2, PRDX5, TXNDC17 and VCP. Focusing on VCP, we uncover a previously unrecognized signaling axis in which GPCR activity modulates activation of the ER stress-induced unfolded protein response. Using a gel-based "library-versus-proteome" assay, we screen over 800 analogues within two days and identify a more potent VCP ligand with nanomolar activity and in vivo antitumor efficacy. This work establishes library-versus-proteome screening as a scalable strategy for ligand discovery.

Indexed as

Combinatorial Chemistry TechniquesDrug DiscoveryProteomeProteomicsAnimalsCell Line, TumorCell ProliferationCysteineHumansLigandsMiceSmall Molecule LibrariesCysteineLigandsProteomeSmall Molecule Libraries

Identifiers

PMID42321189
PMCPMC13434135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.